{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:41:29Z","timestamp":1762875689341,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.4158\/ep14575.dscr","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T17:40:48Z","timestamp":1435858848000},"page":"668-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Management of Acromegaly Patients: What is the Role of Pre-Operative Medical Therapy?"],"prefix":"10.1016","volume":"21","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Katznelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP14575.DSCR_bb0010","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mce.2007.11.024","article-title":"Somatostatin agonists for treatment of acromegaly","volume":"286","author":"Ben-Shlomo","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.4158\/EP14575.DSCR_bb0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: A consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP14575.DSCR_bb0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrendo.2009.143","article-title":"Pituitary function: Acromegaly: where are we now?","volume":"5","author":"Katznelson","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP14575.DSCR_bb0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MED.0b013e32816e06cc","article-title":"Current thinking on the management of the acromegalic patient","volume":"14","author":"Katznelson","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.4158\/EP14575.DSCR_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ncpendmet0096","article-title":"Drug insight: primary medical therapy of acromegaly","volume":"2","author":"Katznelson","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0035","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"issue":"suppl 4","key":"10.4158\/EP14575.DSCR_bb0040","first-page":"1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u2013 2011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"key":"10.4158\/EP14575.DSCR_bb0045","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4158\/EP14575.DSCR_bb0050","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.3171\/2010.7.FOCUS10154","article-title":"Acromegaly: a review of current medical therapy and new drugs on the horizon","volume":"29","author":"Fleseriu","year":"2010","journal-title":"Neurosurg Focus"},{"key":"10.4158\/EP14575.DSCR_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP14575.DSCR_bb0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1210\/jc.2013-2450","article-title":"A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk","volume":"99","author":"Sherlock","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0065","first-page":"329","article-title":"Advances in the pharmacotherapy of patients with acromegaly","volume":"17","author":"Fleseriu","year":"2014","journal-title":"Discov Med"},{"key":"10.4158\/EP14575.DSCR_bb0070","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jcem-67-5-1040","article-title":"Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate","volume":"67","author":"Barkan","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"10.4158\/EP14575.DSCR_bb0075","first-page":"18","article-title":"Presurgical octreotide treatment in acromegaly","volume":"129","author":"Stevenaert","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.4158\/EP14575.DSCR_bb0080","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1210\/jcem.84.10.6027","article-title":"Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls","volume":"84","author":"Biermasz","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3171\/jns.2006.104.6.899","article-title":"Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates","volume":"104","author":"Losa","year":"2006","journal-title":"J Neurosurg"},{"key":"10.4158\/EP14575.DSCR_bb0090","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of octreotide pretreatment on surgical outcome in acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0095","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1210\/jc.2008-1351","article-title":"Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question","volume":"93","author":"Beckers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0100","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/cen.12553","article-title":"Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?","volume":"81","author":"Jacob","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP14575.DSCR_bb0105","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0110","first-page":"2779","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","article-title":"Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review","volume":"14","author":"Fleseriu","year":"2011","journal-title":"Pituitary"},{"key":"10.4158\/EP14575.DSCR_bb0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-14-0249","article-title":"Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial","volume":"171","author":"Fougner","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP14575.DSCR_bb0125","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1507\/endocrj.K10E-203","article-title":"Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study","volume":"57","author":"Shen","year":"2010","journal-title":"Endocr J"},{"key":"10.4158\/EP14575.DSCR_bb0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/147323001204000213","article-title":"Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma","volume":"40","author":"Li","year":"2012","journal-title":"J Int Med Res"},{"key":"10.4158\/EP14575.DSCR_bb0135","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-09-0908","article-title":"Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial","volume":"162","author":"Mao","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP14575.DSCR_bb0140","doi-asserted-by":"crossref","first-page":"e61523","DOI":"10.1371\/journal.pone.0061523","article-title":"Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis","volume":"8","author":"Pita-Gutierrez","year":"2013","journal-title":"PLoS One"},{"key":"10.4158\/EP14575.DSCR_bb0145","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP14575.DSCR_bb0155","first-page":"181","article-title":"Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas","volume":"37","author":"Zhang","year":"2015","journal-title":"A meta-analysis. Brain Dev"},{"key":"10.4158\/EP14575.DSCR_bb0160","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","article-title":"Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles","volume":"45","author":"Astruc","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.4158\/EP14575.DSCR_bb0165","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1517\/17425255.2010.513700","article-title":"Pharmacokinetic evaluation of lanreotide","volume":"6","author":"Hu","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.4158\/EP14575.DSCR_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1011416112730","article-title":"Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly","volume":"3","author":"Lorcy","year":"2000","journal-title":"Pituitary"},{"key":"10.4158\/EP14575.DSCR_bb0175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1756-0500-4-344","article-title":"Pharmacokinetic and technical comparison of Sandostatin(R) LAR(R) and other formulations of long-acting octreotide","volume":"4","author":"Petersen","year":"2011","journal-title":"BMC Res Notes"},{"key":"10.4158\/EP14575.DSCR_bb0180","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/0194599813507236","article-title":"Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors","volume":"149","author":"Friedel","year":"2013","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.4158\/EP14575.DSCR_bb0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/EJA.0b013e32831bc6fb","article-title":"Intubation in patients with acromegaly: experience in more than 800 patients","volume":"26","author":"Khan","year":"2009","journal-title":"Eur J Anaesthesiol"},{"key":"10.4158\/EP14575.DSCR_bb0190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000095535","article-title":"Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs","volume":"83","author":"Tolis","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP14575.DSCR_bb0195","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00000542-200007000-00020","article-title":"Difficult intubation in acromegalic patients: incidence and predictability","volume":"93","author":"Schmitt","year":"2000","journal-title":"Anesthesiology"},{"key":"10.4158\/EP14575.DSCR_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/oxfordjournals.bja.a013400","article-title":"Anaesthetic complications of acromegaly","volume":"84","author":"Seidman","year":"2000","journal-title":"Br J Anaesth"},{"key":"10.4158\/EP14575.DSCR_bb0205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0002-9343(02)01094-X","article-title":"High output heart failure in patients with newly diagnosed acromegaly","volume":"112","author":"Damjanovic","year":"2002","journal-title":"Am J Med"},{"key":"10.4158\/EP14575.DSCR_bb0210","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0002-9149(99)00135-6","article-title":"Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)","volume":"83","author":"Hradec","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP14575.DSCR_bb0215","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/BF03344070","article-title":"Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study","volume":"25","author":"Lombardi","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP14575.DSCR_bb0220","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/jcem.84.1.5368","article-title":"Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP14575.DSCR_bb0230","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:44Z","timestamp":1761515924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20356743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1530891X20356743"],"URL":"https:\/\/doi.org\/10.4158\/ep14575.dscr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Management of Acromegaly Patients: What is the Role of Pre-Operative Medical Therapy?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP14575.DSCR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}